CervoMed (NASDAQ:CRVO) Upgraded at Brookline Cap M

Brookline Cap M upgraded shares of CervoMed (NASDAQ:CRVO) to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports. Brookline Cap M also issued estimates for CervoMed’s Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($2.65) EPS.

CRVO has been the subject of a number of other research reports. Brookline Capital Acquisition raised shares of CervoMed to a “strong-buy” rating in a research report on Tuesday. Cantor Fitzgerald began coverage on shares of CervoMed in a research note on Thursday, December 18th. They set an “overweight” rating on the stock. D. Boral Capital reissued a “buy” rating and issued a $31.00 target price on shares of CervoMed in a research report on Tuesday, December 2nd. Zacks Research raised shares of CervoMed from a “strong sell” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CervoMed in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.17.

CervoMed Stock Performance

Shares of NASDAQ:CRVO traded up $0.71 during trading on Tuesday, hitting $5.31. The company’s stock had a trading volume of 105,761 shares, compared to its average volume of 81,486. The company has a market capitalization of $49.13 million, a PE ratio of -1.83 and a beta of -0.82. CervoMed has a fifty-two week low of $1.92 and a fifty-two week high of $16.94. The stock’s 50-day moving average price is $7.45 and its two-hundred day moving average price is $8.16.

CervoMed (NASDAQ:CRVO) last issued its quarterly earnings data on Friday, November 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). CervoMed had a negative net margin of 415.27% and a negative return on equity of 76.78%. The business had revenue of $0.32 million for the quarter, compared to analyst estimates of $1.43 million. On average, equities analysts predict that CervoMed will post -1.88 earnings per share for the current fiscal year.

Insider Activity at CervoMed

In related news, CEO John J. Alam bought 10,793 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was bought at an average cost of $8.46 per share, for a total transaction of $91,308.78. Following the completion of the purchase, the chief executive officer directly owned 12,500 shares in the company, valued at approximately $105,750. The trade was a 632.28% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sylvie Gregoire bought 10,807 shares of the stock in a transaction dated Monday, November 17th. The shares were bought at an average cost of $8.46 per share, with a total value of $91,427.22. Following the completion of the acquisition, the director directly owned 12,500 shares of the company’s stock, valued at approximately $105,750. The trade was a 638.33% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 92,000 shares of company stock valued at $737,723 in the last quarter. Insiders own 35.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in CervoMed by 1.0% in the third quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock worth $2,779,000 after buying an additional 3,445 shares during the period. Jane Street Group LLC bought a new position in shares of CervoMed during the second quarter worth about $414,000. Citizens Financial Group Inc. RI increased its holdings in shares of CervoMed by 23.0% in the 4th quarter. Citizens Financial Group Inc. RI now owns 37,477 shares of the company’s stock worth $296,000 after acquiring an additional 7,000 shares during the period. Citadel Advisors LLC acquired a new stake in shares of CervoMed in the 3rd quarter worth about $247,000. Finally, Perigon Wealth Management LLC lifted its position in CervoMed by 66.0% in the 3rd quarter. Perigon Wealth Management LLC now owns 28,731 shares of the company’s stock valued at $232,000 after purchasing an additional 11,425 shares during the last quarter. Institutional investors and hedge funds own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.